☰

Amol A. Padgaonkar, Ph.D. - Publications

Affiliations: 
2014 Molecular Biology and Genetics Temple University, Philadelphia, PA, United States 
Area:
Molecular Biology, Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Sato K, Padgaonkar AA, Baker SJ, Cosenza SC, Rechkoblit O, Subbaiah DRCV, Domingo-Domenech J, Bartkowski A, Port ER, Aggarwal AK, Ramana Reddy MV, Irie HY, Premkumar Reddy E. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nature Communications. 12: 4671. PMID 34344863 DOI: 10.1038/s41467-021-24878-z  0.388
2020 Sato K, Padgaonkar A, Cosenza S, Baker S, Reddy R, Reddy EP, Irie HY. Abstract P5-05-04: A novel inhibitor of cancer stem cells overcomes chemotherapy resistance of triple negative breast cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-05-04  0.502
2018 Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, Pallela V, Venkata Subbaiah D, Cosenza SC, Baker SJ, Ramana Reddy MV, Aggarwal A, Reddy EP. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget. 9: 37753-37765. PMID 30701029 DOI: 10.18632/Oncotarget.26514  0.553
2015 Padgaonkar A, Cosenza S, Pallela V, Drc VS, Reddy MR, Reddy EP. Abstract 4453: The dual CK2/TNIK inhibitor, ON108600 targets cancer stem cells and induces apoptosis of paclitaxel resistant triple-negative breast cancer cells Cancer Research. 75: 4453-4453. DOI: 10.1158/1538-7445.Am2015-4453  0.513
2014 Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR, Billa VK, Subbaiah DR, Bharathi EV, Vasquez-Del Carpio R, Padgaonkar A, Baker SJ, Reddy EP. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). Journal of Medicinal Chemistry. 57: 578-99. PMID 24417566 DOI: 10.1021/Jm401073P  0.55
2014 Roychowdhury A, Duraiswamy AJ, Maddi S, Deb C, Mitra S, Reddy R, Maniar M, Jatiani S, Cosenza SC, Padgaonkar A, Reddy P. Abstract 4537: Pharmacokinetics of PLK2 inhibitor GBO-006-1, developed as a novel first-in-class molecule to treat triple negative breast cancer Cancer Research. 74: 4537-4537. DOI: 10.1158/1538-7445.Am2014-4537  0.439
2013 Godse P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar S, Joshi A, Bhatia D, Desai N, Damre A, Bhonde M, Joshi K, Sharma R, et al. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways. Anti-Cancer Agents in Medicinal Chemistry. 13: 1460-6. PMID 24102269 DOI: 10.2174/18715206113136660341  0.479
2013 Reddy MV, Mallireddigari MR, Pallela VR, Cosenza SC, Billa VK, Akula B, Subbaiah DR, Bharathi EV, Padgaonkar A, Lv H, Gallo JM, Reddy EP. Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. Journal of Medicinal Chemistry. 56: 5562-86. PMID 23750455 DOI: 10.1021/Jm400575X  0.518
2013 Padgaonkar A, Rechkoblit O, Cosenza S, Pallela VR, Drc VS, Reddy MR, Aggarwal A, Reddy EP. Abstract 3239: Discovery and biological characterization of ON108600, a small molecule inhibitor of protein kinase CK2. Cancer Research. 73: 3239-3239. DOI: 10.1158/1538-7445.Am2013-3239  0.541
2012 Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer and Prostatic Diseases. 15: 15-27. PMID 22083267 DOI: 10.1038/Pcan.2011.51  0.457
2012 Joshi KS, Padgaonkar A, Rathos M, Wagh V, Manohar S, Bhatia D, Damre A, Sivakumar M, Sharma S. Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity Cancer Research. 72: 3054-3054. DOI: 10.1158/1538-7445.Am2012-3054  0.539
2011 Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Sonawane V, Rathos MJ, Kumar S, Joshi KS. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. Bmc Cancer. 11: 338. PMID 21819554 DOI: 10.1186/1471-2407-11-338  0.436
2010 Yewalkar N, Deore V, Padgaonkar A, Manohar S, Sahu B, Kumar P, Jalota-Badhwar A, Joshi KS, Sharma S, Kumar S. Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery. Bioorganic & Medicinal Chemistry Letters. 20: 6426-9. PMID 20932758 DOI: 10.1016/J.Bmcl.2010.09.083  0.44
2009 Sotillo E, Garriga J, Padgaonkar A, Kurimchak A, Cook JG, Graña X. Coordinated activation of the origin licensing factor CDC6 and CDK2 in resting human fibroblasts expressing SV40 small T antigen and cyclin E. The Journal of Biological Chemistry. 284: 14126-35. PMID 19321444 DOI: 10.1074/Jbc.M900687200  0.368
2008 Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, Bhatia D, Rathos M, Joshi K, Vishwakarma RA, Kumar S. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway Bioorganic and Medicinal Chemistry Letters. 18: 3603-3606. PMID 18501601 DOI: 10.1016/J.Bmcl.2008.04.078  0.489
Show low-probability matches.